The two marijuana stocks have performed pretty well so far this year, but they’re a long way from delivering 100% gains.
I fully expect that Ayr and Cresco will continue to benefit from the expanding cannabis markets where they already have established operations.
Ayr recently closed on its purchase of Liberty Health Sciences, a deal that gives the company the fourth-biggest retail footprint in Florida’s medical cannabis market.
Legislative efforts are under way to remove restrictions that limit cannabis companies from accessing traditional banking services and to remove marijuana from the Controlled Substances Act.
That would pave the way for Ayr and Cresco to list their shares on a major U.S.
However, while it’s by no means a slam dunk, I think there is a realistic path for both stocks to double in the second half of 2021.